Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Paion AG completes phase II study with remimazolam in indication anaesthesia


Tuesday, 11 Feb 2014 01:30am EST 

Paion AG:Announces the successful completion of the recruitment of the Phase II clinical trial with the short-acting anaesthetic/sedative Remimazolam in the indication 'anaesthesia' in patients undergoing cardiac surgery.Says no drug-related Serious Adverse Event has been reported. 

Company Quote

1.878
-0.062 -3.20%
23 Dec 2014